Lund Cecilia Margareta, Dyhl-Polk Anne, Nielsen Dorte Lisbeth, Riis Lene Buhl
Department of Medicine, Copenhagen University Hospital, Herlev and Gentofte, Denmark; Copenage, Copenhagen Center for Clinical Age Research, University of Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Denmark.
Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, Denmark.
Transl Oncol. 2021 Jan;14(1):100892. doi: 10.1016/j.tranon.2020.100892. Epub 2020 Oct 9.
Cancer metastases accounts for most cancer deaths. The secreting glycoprotein Wnt5a impairs tumor cell migration and reduces invasiveness and metastasis. High Wnt5a expression in tumor cells is correlated to better outcomes in patients with breast, prostate and epithelial ovarian cancer. We aimed to investigate the association between the Wnt5a expression and outcomes in patients with colon cancer (CC) stage II/III. We performed a retrospective single-center study evaluating 345 patients with radical resection for primary CC, stage II/III, who started 6 months of adjuvant chemotherapy with 5-FU or capecitabine ± oxaliplatin between 2001 and 2015. Archived formalin-fixed paraffin embedded tumor tissue from resection specimens were stained with Wnt5a antibody using immunohistochemistry. Cytoplasmatic Wnt5a staining was assessed according to intensity and percentage of stained cells. Patients were divided in groups depending on high (n = 230) or low (n = 115) Wnt5a expression. Disease free survival (DFS) and overall survival (OS) were analyzed for the two groups using Kaplan-Meier plots and Long rank test. Patients with Wnt5a-negative tumors had significantly poorer performance status (PS) than patients with high Wnt5a expression (p = 0.046). No significant difference was seen between patients with low and high Wnt5a expression in terms of 5-year DFS (p = 0.517) or 5-year OS (p = 0.415). Poor PS was associated with lower DFS (p = 0.002) and OS (p < 0.001). In conclusion, we found no significant difference in prognosis for patients with stage II/III CC depending on their Wnt5a expression. Patients with Wnt5a-negative tumors had significant poorer PS than patients with higher levels. Poor PS was associated with lower DFS and OS.
癌症转移是大多数癌症死亡的原因。分泌型糖蛋白Wnt5a会损害肿瘤细胞迁移，并降低侵袭性和转移能力。肿瘤细胞中高表达Wnt5a与乳腺癌、前列腺癌和上皮性卵巢癌患者的较好预后相关。我们旨在研究Wnt5a表达与II/III期结肠癌（CC）患者预后之间的关联。我们进行了一项回顾性单中心研究，评估了345例II/III期原发性CC行根治性切除术的患者，这些患者在2001年至2015年间开始接受为期6个月的5-氟尿嘧啶或卡培他滨±奥沙利铂辅助化疗。使用免疫组织化学方法，用Wnt5a抗体对切除标本中存档的福尔马林固定石蜡包埋肿瘤组织进行染色。根据染色细胞的强度和百分比评估细胞质Wnt5a染色。根据Wnt5a高表达（n = 230）或低表达（n = 115）将患者分组。使用Kaplan-Meier曲线和长秩检验分析两组的无病生存期（DFS）和总生存期（OS）。Wnt5a阴性肿瘤患者的体能状态（PS）明显比Wnt5a高表达患者差（p = 0.046）。Wnt5a低表达和高表达患者在5年DFS（p = 0.517）或5年OS（p = 0.415）方面无显著差异。较差的PS与较低的DFS（p = 0.002）和OS（p < 0.001）相关。总之，我们发现II/III期CC患者的预后根据其Wnt5a表达无显著差异。Wnt5a阴性肿瘤患者的PS明显比水平较高患者差。较差的PS与较低的DFS和OS相关。
